Vascepa refills up over 12%, double digit base growth too. On track to meet or exceed FY analyst revenue estimates.
Lovaza and Niacin share directly going to Vascepa.
GSK has to be talking to AMRN at this point.
Vascepa refills up over 12%, double digit base growth too. On track to meet or exceed FY analyst revenue estimates.
Lovaza and Niacin share directly going to Vascepa.
GSK has to be talking to AMRN at this point.
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.